Key points at a glance
The short version, with every number taken from the Foundayo™ prescribing information, revised 07/2026.
Nausea is the top effect
In two placebo-controlled weight trials, nausea was reported by 26% to 35% of adults on Foundayo™ compared with 10% on placebo. Constipation, diarrhea and vomiting each reached more than 20% at the higher doses.
Most stomach effects were mild or moderate
About 60% to 69% of people on Foundayo™ reported a stomach effect, compared with 37% on placebo. Among those who did, 60% reported it as mild, 36% as moderate and 4% as severe.
Some stopped because of side effects
Across both trials, 8% of people on Foundayo™ stopped because of side effects, compared with 3% on placebo. Stomach effects were the most common reason: 5% of people on Foundayo™ stopped because of them.
The label carries a boxed warning
Like other GLP-1 medicines, Foundayo™ has a boxed warning about thyroid C-cell tumors. Its label also lists pancreatitis, severe stomach effects, kidney injury, low blood sugar, gallbladder disease and allergic reactions.
Common effects and how often they appeared
The table is the label's Table 1: side effects reported by at least 5% of people on Foundayo™, and more often than on placebo, in a pool of two placebo-controlled trials in adults with obesity or overweight, with or without type 2 diabetes. The doses in the column headings are the trial arms on the label, not a recommendation. Read each column against placebo: some of these symptoms happen to people taking nothing.
| Side effect | Placebo | Foundayo™ 5.5 mg | Foundayo™ 9 mg | Foundayo™ 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Indigestion (dyspepsia) | 4% | 12% | 16% | 13% |
| Stomach pain | 7% | 13% | 14% | 14% |
| Headache | 7% | 8% | 9% | 9% |
| Bloating (abdominal distension) | 3% | 7% | 9% | 8% |
| Fatigue | 4% | 6% | 7% | 9% |
| Burping (eructation) | 1% | 6% | 8% | 8% |
| Reflux (GERD) | 2% | 6% | 6% | 7% |
| Gas (flatulence) | 2% | 5% | 6% | 6% |
| Hair loss | 2% | 4% | 4% | 5% |
Nausea and vomiting
Nausea was reported by 26%, 34% and 35% of people at the three doses studied, versus 10% on placebo. Vomiting rose with the dose, from 13% to 24%, compared with 4% on placebo.
Constipation and diarrhea
Constipation was reported by 20% to 27% of people on Foundayo™ versus 9% on placebo. Diarrhea was reported by 21% to 25% versus 11%.
Indigestion, stomach pain and bloating
Indigestion was reported by 12% to 16% and stomach pain by 13% to 14%, compared with 4% and 7% on placebo. Bloating was reported by 7% to 9% versus 3%.
Burping, reflux and gas
Burping, listed as eructation, was reported by 6% to 8% of people on Foundayo™ compared with 1% on placebo. Reflux was reported by 6% to 7% and gas by 5% to 6%. The label does not describe the smell; sulfur burps on a GLP-1 has more on that.
Headache, fatigue and hair loss
Headache was reported by 8% to 9% and fatigue by 6% to 9%, compared with 7% and 4% on placebo. Hair loss was reported by 4% to 5% versus 2%. The label links it with weight reduction and reports it more often in women (7%) than in men (0.9%).
Serious risks listed on the Foundayo™ label
These events are uncommon, but they are the reason a new or unusual symptom should not always be put down to the medicine.
Boxed warning: thyroid C-cell tumors
Foundayo™ carries a boxed warning for thyroid C-cell tumors. The label explains that GLP-1 medicines that are active in rats and mice caused thyroid C-cell tumors in those animals, while orforglipron is not active in rats or mice and did not cause tumors in them. Whether these findings matter for people has not been determined.
Foundayo™ is not for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2). A lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath should be reported to your prescriber.
Pancreatitis
Acute pancreatitis was confirmed in 6 people on Foundayo™ in the trials, about 0.14 per 100 years of exposure, versus 0.04 on placebo. Severe stomach pain that will not go away, sometimes spreading to the back, with or without vomiting, is the symptom to act on.
Kidney injury and severe stomach effects
Severe stomach side effects were reported by about 3% of people on orforglipron versus 1% on placebo. Fluid lost through vomiting or diarrhea can lead to acute kidney injury, reported in 0.2% of people versus 0.05% on placebo. Foundayo™ is not recommended for people with severe gastroparesis.
Heart rate and blood pressure
Average heart rate rose by 4 to 5 beats per minute, and a fast heart rate was reported by 3% versus 0.9% on placebo. Low blood pressure was reported by 2% versus 0.5%, and more often in people also taking blood pressure medicines.
Gallbladder, blood sugar, eyes, allergies and anesthesia
Gallstones were reported by 1% versus 0.7% on placebo. Low blood sugar is more likely with insulin or a sulfonylurea. People with type 2 diabetes and a history of diabetic retinopathy should be monitored. The label also lists serious allergic reactions and a risk of food or liquid entering the lungs during anesthesia or deep sedation.
The label says Foundayo™ may cause harm to an unborn baby, so tell your prescriber if you are pregnant or planning to be.
Symptoms that need attention
This list follows the warnings and Medication Guide in the Foundayo™ label. It is not a complete list and it is not medical advice: if something feels wrong, call.
Seek emergency care
Swelling of the face, lips, tongue or throat, trouble breathing, or fainting need emergency help. Severe stomach pain that does not go away also needs urgent attention.
Call your prescriber
Get in touch about any of these:
- Nausea, vomiting or diarrhea that is severe or will not go away, or signs of dehydration.
- Pain in the upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools, which can be gallbladder signs.
- Shakiness, sweating, dizziness, a fast heartbeat, hunger, headache, blurred vision, confusion or irritability, which can mean low blood sugar, especially with insulin or a sulfonylurea.
- Dizziness or feeling faint, which can come with low blood pressure.
- A racing heartbeat at rest.
- Any change in your vision, if you have type 2 diabetes.
- A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
Other medicines and procedures
The label lists interactions with some other medicines, including strong CYP3A4 inhibitors and inducers and simvastatin, and notes that Foundayo™ may change how other oral medicines are absorbed. Share your full medication list with your prescriber, and tell your care team you take Foundayo™ before any surgery or procedure that uses anesthesia or deep sedation.
Questions about your dose
Questions about your dose, your step-ups or a missed tablet go to your prescriber, and your label has the official missed-dose instructions. This page shares label facts only and does not give dosing advice.
How to report a side effect
The label gives two contacts for reporting a suspected side effect: Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979), or the FDA's MedWatch program at 1-800-FDA-1088.
How a daily pill changes the side effect rhythm
Foundayo™ is taken differently from the weekly GLP-1 shots, and a few label facts help explain what you may notice.
Taken once a day, with or without food
The label says Foundayo™ is taken once daily, with or without food, and swallowed whole, not broken, crushed or chewed. That is a different routine from a once-weekly injection.
A shorter half-life than weekly shots
The label gives an elimination half-life of about 29 to 49 hours. It clears much faster than a weekly injection, which is why it is taken every day.
Monthly step-ups
The label's schedule starts at 0.8 mg once daily, with increases after at least 30 days on each dose, as the prescriber directs. That is the label's schedule, not a plan for you: your prescriber sets yours. In the trials, nausea, vomiting and diarrhea were higher during this escalation period and decreased over time.
Birth control pills
Foundayo™ slows stomach emptying and may affect how oral medicines are absorbed. The label advises people using birth control pills to switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose increase. Talk to your prescriber about which method fits you.
From the makers of this guide
Log the pill and how you feel in one place
The label gives trial averages. Your prescriber needs your version: which symptoms, how strong, and when they started.
- 01
Your daily tablet, on schedule
Log each Foundayo™ tablet against the schedule and step-ups you set from your prescription. On iPhone (iOS 17 and later), a Lock Screen Live Activity counts down to your next dose and has a one-tap Log button, and a missed dose shows as overdue.
- 02
Built-in symptoms, each with a severity
The side-effect tracker has built-in GLP-1 symptoms grouped by area, such as injection site, digestive and head and nerves, plus your own, each saved by day with how severe it was. A short daily check-in asks about food noise, side effects and mood, and you can add questions such as energy and sleep.
- 03
Patterns after a step-up
Your side-effect trend chart sits on the Dose tab beside your dose history, so a rise in nausea in the first week on a new dose, and the settling after it, is easy to point to.
- 04
Meals you can look back on
Log meals by photo scan, barcode or search in Nutrition. Looking back at what you ate on rougher days makes it easier to notice which foods sat well.
Bring your record to follow-up visits
Early follow-up visits matter on a new medicine, and a log helps most when your prescriber can see it.
A PDF report for your prescriber
Pep AI builds a PDF report of your doses, weight and daily meal totals. Show it on your phone or send it before the visit.
Questions worth asking
Ask whether your pattern is expected, what should prompt a call, and whether any of your other medicines interact with Foundayo™. Your prescriber decides whether anything changes.
Keep the log going
A daily tablet means a daily entry, which takes a few seconds once it is routine. The next report is ready whenever you need it.
More from Pep AI
For an overview across GLP-1 medicines, read GLP-1 side effects. For nausea in particular, see GLP-1 nausea, and for how the symptom log works, the side effects tracker.
Key takeaways
- Nausea was the most common Foundayo™ side effect in the trials: 26% to 35% of adults, versus 10% on placebo.
- Most stomach effects were mild or moderate, and nausea, vomiting and diarrhea were higher during dose escalation, then decreased.
- 8% of people stopped Foundayo™ because of side effects in the trials, versus 3% on placebo.
- Foundayo™ carries the boxed thyroid C-cell tumor warning, and its label lists pancreatitis, kidney injury, gallbladder disease, low blood sugar and allergic reactions.
- Questions about your dose, step-ups or a missed tablet belong with your prescriber and your label.
Keep a record your prescriber can use.
Pep AI logs your daily tablet, symptoms with severity, meals and weight, and makes a PDF of your doses, weight and meal totals. Download Pep AI on iPhone or Android.
Frequently asked questions
Keep reading
Sources
This page summarizes the Foundayo™ prescribing information (revised 07/2026). It is general information, not medical advice, and does not replace your prescriber or pharmacist. Pep AI is not affiliated with or endorsed by Eli Lilly and Company. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026